GBC-11004 / Gradiant Bioconvergence - LARVOL DELTA

GBC-11004: An AI-Identified Kinase Target to Overcome Osimertinib Resistance in NSCLC Patient-Derived Organoids [WITHDRAWN] (ESMO 2025) - No abstract available

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

GBC-11004: An AI-Driven Novel Kinase Target With Potential to Overcome Osimertinib Resistance in NSCLC (IASLC-WCLC 2025) - "Notably, combination therapy (Osimertinib + GBC-11004 inhibitor) demonstrated significantly improved sensitivity compared to Osimertinib monotherapy in multiple resistant PDO models. Conclusions : These findings highlight the potential of GBC-11004 as a novel therapeutic target for overcoming Osimertinib resistance in NSCLC, reinforcing the robustness of the PDO-based AI-driven platform for target discovery in identifying high-priority, novel therapeutic targets."

Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

GBC-11004: An AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC. (ASCO 2025) - "Our results demonstrate the potential of GBC-11004 as a novel therapeutic target for overcoming Osimertinib resistance in NSCLC treatment and emphasize the capability of our PDO-based AI-driven target discovery platform in identifying high-priority novel targets."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Gradient Bioconvergence Unveils Novel Non-Small Cell Lung Cancer Therapeutic Target at ASCO 2025 [Google translation] (BioTimes) - "At this conference, Gradient Bioconvergence will present its latest research results on 'GBC-11004', a new treatment target for non-small cell lung cancer...The company effectively derived the resistance gene that was difficult to identify with existing next-generation sequencing (NGS) analysis alone, and proved that GBC-11004 is effective as a therapeutic target by performing CRISPR-based gene editing and PDO-based drug evaluation."

Preclinical • Non Small Cell Lung Cancer

Combining AI-Based Target Discovery with CRISPR/Cas9 Editing: Validating GBC-11004 as a Novel Target to Combat Osimertinib-Resistant NSCLC (ASGCT 2025) - "In summary, the findings of this study demonstrate the potential of integrating AI-driven target identification to advance therapeutic strategies in epidermal growth factor receptor-mutated NSCLC, providing a novel prospect for improved patient outcomes. Disease Focus of Abstract:Cancer Solid Tumors"

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Gradient Bioconvergence Unveils New Non-Small Cell Lung Cancer Target at 'AACR 2025'∙∙∙ Active Discussion on Global Cooperation [Google translation] (BioTimes) - "'GBC-11004', which was first unveiled through a poster presentation at this conference, is a new target derived from the world's largest cancer patient-derived organoid (PDO) big data of over 800 types built by Gradient Bioconvergence and an artificial intelligence (AI)-based target discovery platform. It is a new kinase that is overexpressed in non-small cell lung cancer (NSCLC) patients who are resistant to third-generation EGFR inhibitors. In particular, when the GBC-11004 inhibitor was administered in combination with existing third-generation EGFR inhibitors, a significant improvement in suppressing the resistance response was observed, drawing attention from the field."

Preclinical • Non Small Cell Lung Cancer

GBC-11004: an AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC (AACR 2025) - "Furthermore, we have initiated lead compound optimization by preliminary IC50 analyses using compounds targeting GBC-11004 and observed significantly enhanced sensitivity in the combination therapy group (Osimertinib + GBC-11004 inhibitor) compared to the Osimertinib monotherapy group in resistant PDO models. Our results demonstrate the potential of GBC-11004 as a novel therapeutic target for overcoming Osimertinib resistance in NSCLC treatment and emphasize the capability of our PDO-based AI-driven target discovery platform in identifying high-priority novel targets."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Gradient Bioconvergence to Debut ‘New Non-Small Cell Lung Cancer Treatment Target’ at AACR 2025 [Google translation] (BioTimes) - "At this conference, Gradient Bioconvergence will unveil for the first time 'GBC-11004', a new treatment target for non-small cell lung cancer, and present its latest research results and technologies, including this, through three posters....In addition, two other presentations will introduce the results of efficacy evaluation of targeted anticancer drugs and immunotherapy drugs using a PDO-only evaluation model and an immune cell co-culture model, and the development of a cancer metastasis model using a vascular co-culture platform."

Preclinical • Non Small Cell Lung Cancer